The mitochondrial disease therapies market, valued at USD 518 million in 2025 to reach USD 660 million in 2026 and USD 1,817 million by 2030, with a higher CAGR of 28.8% during the forecast period, 2026 to 2030. Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA (a small, circular, double-stranded with ~16,500 base pairs that exists outside of the nucleus). It is worth highlighti...

The global cancer diagnostics market is currently worth around USD 156 billion and is expected to reach USD 319 billion by 2032. It is expected to grow at a CAGR of 9.3% till 2032. According to the American Cancer Society, by 2050, the number of cancer cases will be predicted to increase to 35 million based solely on projected population growth. Further, Studies have indicated that misdiagnosis or late diagnosis can severely impact survival rates, underscoring the critical need for reliable diag...

The cytotoxic drugs and HPAPI manufacturing market, valued at USD 13.98 billion in 2025, is projected to grow to USD 15.59 billion in 2026 and USD 46.41 billion by 2035, representing a CAGR of 12.89% during the forecast period 2026 to 2035. Around 40% of approved drugs in the market are classified as highly potent. Of these, 60% of the approved HPAPI-based drugs are used for cancer treatment, owing to their ability to exhibit highly effective therapeutic responses with minimal dosage.

The NFT in Healthcare market, valued at USD 208 million in 2025, is projected to reach USD 240 million in 2026 and USD 1,117 million by 2035, with a 18.6% CAGR during the forecast period 2026 to 2035. The new research study consists of market trends, porter’s five forces, detailed market analysis, and market sizing and opportunity analysis.

The global healthcare cold chain logistics market is estimated to grow from USD 197.7 billion in 2024 to reach USD 207.0 billion in 2025 and USD 320.9 billion by 2035, representing a higher CAGR of 4.5% during the forecast period. Given the recent technical breakthroughs and advances, and the steadily rising demand for biopharmaceuticals, the reliance on cold chain is expected to increase substantially, causing logistics service providers to contemplate, devise and implement flexible business st...

The global T-cell therapy market, valued at USD 6.5 billion in 2025, is projected to grow to USD 8.1 billion in 2026 and USD 20.9 billion by 2035, representing a CAGR of 11.2% during the forecast period 2026 to 2035. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone. The US FDA approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or r...

Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women

The global site management organization market, valued at USD 12.4 billion in 2025, is projected to reach USD 13.6 billion in 2026 and USD 31.6 billion by 2035, with a 9.8% CAGR during the forecast period 2026 to 2035. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually. Currently, around 250 companies claim to be actively providing SMO services to drug...

Currently, more than 40 industrial and non-industrial players are engaged in the development of drugs for polycystic ovary syndrome. Notably, 70% of the industrial players are very large firms. It is worth noting that these industrial players are widely emphasizing symptomatic treatment of polycystic ovary syndrome. However, with widespread demand companies like AstraZeneca are currently evaluating clinical drugs to cure PCOS condition.

The global healthcare simulators market size, valued at USD 3.04 billion in 2024, is projected to reach USD 3.61 billion in 2025 and USD 14.49 billion by 2035, representing a CAGR of 14.9% during the forecast period. It is worth mentioning that the need for healthcare simulators has significantly increased due to the growing medical education systems where practitioners / students can improve their skills using these innovative technologies. Driven by the ongoing demand, several industrial playe...

The widespread adoption of DNA methylation technologies and broad emphasis on genome research have become crucial growth factors for this industry. It is worth noting that industrial players, such as Pfizer, Roche, QIAGEN are finding key opportunities in this field and focusing on technological innovations to make them more advanced and affordable. For instance, in April 2025, EpiCypher® (a global leader in epigenomic innovation) launched CUTANA® meCUT&RUN and Multiomic CUT&RUN (affordable met...

The global tele-intensive care unit market size is likely to be worth USD 4.12 billion in 2025 and will reach USD 15.2 billion by 2035. In terms of the type of component, hardware segment is currently holding the highest share of the market due to the increasing demand for communication channels and video consultation tools for delivering remote care. Some of the potential opportunities in this field are technological innovations, and demand robust connectivity solutions.

The global veterinary hematology analyzers market is valued at USD 1.03 billion in 2025 and is poised to reach USD 1.74 billion by 2035, expecting to grow at a CAGR of 5.4% during the forecast period. The market is expected to be driven by the rising demand for advanced diagnostics tools, such as veterinary hematology analyzers and handheld analyzers for diagnosing infectious diseases in animals. Driven by the ongoing demand, several market players are expected to strengthen their product portfo...

Majority of the industrial players, such as Abbott Laboratories, B. Braun and Johnson & Johnson are continually accelerating their efforts to develop single use medical kits and other supplies. In order to leverage competitive edge, several industrial players are undertaking strategic initiatives, such as latest product launch, collaborations, and partnerships.For instance, in October 2024, Verathon (subsidiary of Roper Industries) launched first Spectrum QC eco (single-use video laryngoscope) m...

The industrial players such as Merck, Thermo Fisher Scientific and STEMCELL Technologies are increasingly emphasizing adult stem cells specifically those collected from adipose tissues / bone marrow to repair tissue damage and development of stem cell therapies for targeting wide range of diseases. In April 2025, Abu Dhabi Biobank launched an affordable private cord blood banking which offers an affordable and accessible way to preserve their newborns stem cells.

In Asia-Pacific, the market for non-invasive fat reduction is expected to register a higher CAGR during the forecast period. This lucrative growth is likely to be fueled by the heightened social media influence and adoption of aesthetic procedures for body contouring and fat reduction. Additionally, the companies like AbbVie, and VLCC are expanding their clinical proven technologies such as CoolSculpting Elite and VLCC Lipo-1060 latest laser technology for far reduction, in Asian countries, such...

It is important to highlight here that the USFDA has also approved numerous cancer biosimilar products for cancer treatment, such as bevacizumab, rituximab and trastuzumab. Notably, biosimilars of bevacizumab (Avastin®) are presently available with brand name, Alymsys®, Avzivi®, Jobevne™, Mvasi®, Vegzelma® and Zirabev®. The market for oncology biosimilars in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. Notably, the rising prevalence of cancer is expected...

The global TIL therapy market, valued at USD 0.3 billion in 2025, is projected to reach USD 0.6 billion in 2026 and USD 4.2 billion by 2035, with a 23.4% CAGR during the forecast period 2026 to 2035. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, Natural killer cell therapies and macrophages isolated from the tumor. Notably, over 75 TIL cell therapy are being evaluated across different stages of preclinical / clinical development, either as mono...

The TCR therapy market, valued at USD 442 million in 2025, is projected to reach USD 533 million in 2026 and USD 1,563 million by 2035, with a 12.7% CAGR during the forecast period 2026 to 2035, mainly driven by the need for targeted cancer treatment for solid tumors. Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 T cell receptor based immunotherapies for the treatment of various oncological and non-oncological disorders. Furt...

The medical device labeling market, valued at USD 333 million in 2025, is projected to reach USD 365 million in 2026 and USD 509 million by 2030, with a CAGR of 8.6% during the forecast period 2026 to 2035. As of August, over 30 medical devices were approved by the US FDA alone, in 2019. However, it is worth highlighting that more than 10% of product recalls observed in this market are attributed to medical device labeling related issues. Therefore, owing to the expertise and infrastructure req...